Activation of nuclear factor κB inflammatory bowel disease

Gut

Volumn 42, Issue 4, 1998, Pages 477-484

  Schreiber, S ^a,b   Nikolaus, S ^a   Hampe, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Inflammatory bowel disease; Interleukin 1 ; Intestinal immunity; Signal transduction; Steroids; Tumour necrosis factor

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOREGULATION; LAMINA PROPRIA; MALE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS;

EID: 0031925362     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.4.477     Document Type: Article

References (41)

1. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-ß by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989;30:835-8.
2. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease: enhanced production during active disease. Gut 1990;31:686-9.
3. MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
4. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-α, interleukin-1ß and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
5. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroemerology 1992;103:1587-95.
6. Reinecker H-C, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
7. Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhea. J Clin Pathol 1992;46:757-60.
8. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58:227-9.
9. Baldwin AS. The NF-KB and I-KB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-81.
10. Hassanain HH, Dai W, Gupta SL. Enhanced gel mobility shift assay for DNA-binding factors. Anal Biochem 1993;213:162-7.
11. Brown K, Gerstberger S, Carlson L, et al. Control of IκB-α proteolysis by site-specific signal induced phosphorylation. Science 1995;267:1485-7.
12. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I-kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-41.
13. Scherer DC, Brockman JA, Chen Z, et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 1995;92:11259-63.
14. Kim H, Lee HS, Chang KT, et al. Chlormethyl ketones block induction of nitric oxide synthase in murine macropahges by preventing activation of nuclear factor-kappa B. J Immunol 1995;154:4741-8.
15. Shakhov AN, Collart MA, Vassali P, et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 1990;171:35-47.
16. Kunsch C, Rosen CA. NF-kappa B subunit specific regulation in the interleukin-8 promoter. Mol Cell Biol 1993;13: 6137-46.
17. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995;270:933 43.
18. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 1993;151:6986 93.
19. Ziegler-Heitbrock HW, Wedel A, Schraut W, et al. Tolerance to lipopolysaccharides involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem 1994;269:17001-4.
20. Neurath MF, Petterson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Medicine 1996;2:998 1004.
21. Schreiber S, MacDermott RP, Raedler A, et al. Increased activation of intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991;101: 1020-30.
22. Schreiber S, Heinig T, Panzer U, et al. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995;108:21-33.
23. Hou J, Schindler U, Henzel WJ, et al. An interleukin-4-induced transcription factor: IL-4 Stat. Science 1994;265: 1701-6.
24. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor and interleukin 1 stimulate the human immunodifficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2335 40.
25. Scholtz B, Lamb K, Rosfjord E, et al. Appearance of nuclear protease after embryonal carcicomal cells undergo differentiation. Dev Biol 1996;173:420 7.
26. Dent CL, Latchman DS. The overlapping octamer/ TAATGARAT motif is a high-affinity binding site for the cellular transcription factors Oct-1 and Oct-2. Biochem J 1991;277:541 5.
27. Henell F, Glaumann H. Effect of leupeptin on the autophagic vacuolar system of rat hepatocytes. Correlation between ultrastructure and degradation of membrane and cytosolic proteins. Lab Invest 1984;51:46 56.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951;193:265 75.
29. Rohringer R, Holden DW. Protein blotting: detection of proteins with colloidal gold, and of glycoproteins and lectins with biotin-conjugated and enzyme probes. Anal Biochem 1985;144:118 27.
30. Fried MG. Measurement of protein-DNA interaction parameters by electrophoretic mobility shift assay. Electrophoresis 1989;10:366-76.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual (2nd ed). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
32. Lilliefors HW. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. Journal of the American Statistical Association 1967;64:399 402.
33. Sachs L. Angeccandte Statistik (7th ed). Heidelberg, New York, Tokyo: Springer, 1992.
34. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statisties 1947;18:50 60.
35. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroemerology 1995;109: 129 35.
36. Baert F, D'Haens G, Geboes K, et al. TNF-α antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis [abstract]. Gastroemerology 1996;110:A940.
37. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr. AS. Role of transcriptional activation by IκB in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283-6.
38. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NFκB activity through induction of IkB synthesis. Science 1995;270:286 90.
39. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956 9.
40. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gatroenterology 1976;70:439 44.
41. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82 6.